ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Registry-linked trialOpen access · bronzeAbstract readCase Reports
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03157129, which is not on this map. Cited by 65 papers.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03157129 no registry record found
Who cites it
65 citing papers in PubMed, 121 citations in OpenAlex.
- Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.Investigational new drugs · 2026Article
- The combination of pralsetinib and bevacizumab enhances antitumor activity against KIF5B-RET lung cancer via PI3K/AKT pathway.Journal of thoracic disease · 2026Article
- Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.Cancer letters · 2026Article
- Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.JCO precision oncology · 2026Article
- Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- How to manage medullary thyroid carcinoma: current treatment strategies.Drugs in context · 2026Review
- MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.Molecular oncology · 2025Article
- Evolving roles of MET as a therapeutic target in NSCLC and beyond.Nature reviews. Clinical oncology · 2025Review
- AdvancingTranslational cancer research · 2025Article
- Review
- Mechanisms of resistance to RET-directed therapies.Endocrine-related cancer · 2025Review
- Article
- Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer.Endocrine · 2024Article
- Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.Cell communication and signaling : CCS · 2024Review
- Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies.MedComm · 2024Review
- Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers andJCO precision oncology · 2024Article
- Article
- Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report.JTO clinical and research reports · 2024Article
- Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.NPJ precision oncology · 2024Article
- Oncogenic alterations in advanced NSCLC: a molecular super-highway.Biomarker research · 2024Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 6 institutions in 1 country.
Ezra Y Rosen *Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Melissa L Johnson *Department of Medicine, Sarah Cannon Cancer Center, Nashville, Tennessee.
Sarah E CliffordLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Romel SomwarDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jennifer F KheraniLoxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.
Jieun SonLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-9862-7706
Arrien A BertramLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Monika A DavareOregon Health and Science University, Portland, Oregon.
Eric GladstoneDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9468-0769
Elena V IvanovaBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Dahlia N HenryLoxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.ORCID 0000-0001-5983-9597
Elaine M KelleyLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-3718-3739
Mika LinLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Marina S D MilanLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Binoj C NairLoxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.
Elizabeth A OlekLoxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.ORCID 0000-0003-4128-249X
Jenna E ScanlonLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Morana VojnicDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5441-4119
Kevin EbataLoxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.
Jaclyn F HechtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Bob T LiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6661-8733
Lynette M ShollDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Barry S TaylorDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Marc LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Pasi A JänneLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
S Michael RothenbergLoxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.
Alexander Drilon *Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. drilona@mskcc.org.ORCID 0000-0001-6806-9061
Geoffrey R Oxnard *Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Dana-Farber Cancer Institute · USMemorial Sloan Kettering Cancer Center · USLoxo Oncology at Lilly (United States) · USBrigham and Women's Hospital · USOregon Health & Science University · USSarah Cannon · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MDevelopment of Combination Therapies to Delay/Prevent Acquired Drug ResistanceR35CA220497 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2018 to 2024
$7.2MCLINICAL SCHOLARS BIOMEDICAL RESEARCH TRAINING PROGRAMT32CA009512 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Ping Chi · 1985 to 2026
$6.3MResistance and Sensitivity to MET Inhibitors in Lung CancerR01CA222823 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2018 to 2022
$1.9MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA222823NCI NIH HHS R35 CA220497NCI NIH HHS T32 CA009512
Abstract
purposeThe PATIENTS AND
methodsWe studied patients treated on the first-in-human clinical trial of selpercatinib (NCT03157129) who were found to have
results
conclusionsThrough the use of SPPs, we were able to offer combination therapy targeting
Indexed as
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungClinical Trials, Phase I as TopicCrizotinibDrug Resistance, NeoplasmFemaleGene AmplificationHumansLung NeoplasmsMaleMiddle AgedOncogene Proteins, FusionPilot ProjectsProtein Kinase InhibitorsCrizotinibMET protein, humanOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene Proteins c-metProto-Oncogene Proteins c-retPyrazolesPyridinesRET protein, humanselpercatinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03157129ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.